Stay updated on INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial
Sign up to get notified when there's something new on the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page.

Latest updates to the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedDifference0.1%
- Check23 days agoChange DetectedDifference0.1%
- Check30 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check37 days agoChange DetectedDifference0.1%
- Check44 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed information about the INTEGA study and its treatment options for advanced esophagogastric adenocarcinoma, while adding new identifiers and collaborators related to gastric cancer research.SummaryDifference39%
Stay in the know with updates to INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTEGA: Ipilimumab & FOLFOX + Nivolumab & Trastuzumab Clinical Trial page.